Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

AbbVie touts positive cariprazine data in major depressive disorder

By Brian Buntz | May 23, 2022

Logos of AbbVie and Gedeon RichterThe schizophrenia and bipolar drug cariprazine (Vraylar) fared well as an adjunctive therapy in a Phase 3 3111-301-001 study involving patients with major depressive disorder (MDD).

AbbVie (NYSE:ABBV) is aiming to win a new FDA indication for the drug as an adjunctive treatment of MDD by the end of the year.

According to MedPage Today, 44% of patients in the 1.5-mg arm had at least a 50% reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) score by week 2 of treatment.

The company did not divulge significant data in a news release, stating that patients receiving a 1.5mg/day dose of the drug met the primary endpoint of statistically significant improvement based on the MADRS at week six compared to placebo. Patients receiving 3.0 mg/day per day had an improved MADRS total score, but the results were not statistically significant.

Patients in the 1.5 mg group also saw improvements in their scores on the Hamilton Depression Rating Scale and Hamilton Rating Scale for Anxiety.

The MDD patients in the study had an inadequate response to ongoing antidepressant therapy.

AbbVie noted that it would present the full results on May 24 at the American Psychiatric Association (APA) Annual Meeting in New Orleans.

The company has filed a supplemental New Drug Application (sNDA) for the drug with data from two positive registration-enabling studies, including Study 3111-301-001.

AbbVie is developing the drug in collaboration with Budapest, Hungary–based Gedeon Richter Plc.

To date, more than 8,000 patients globally have received cariprazine in more than 20 clinical studies involving a spectrum of psychiatric disorders.


Filed Under: clinical trials, Drug Discovery, Psychiatric/psychotropic drugs
Tagged With: AbbVie, cariprazine, Gedeon Richter, major depressive disorder, MDD, schizophrenia, Vraylar
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Mental health
Can the U.S. unify around psychedelics for mental health?
Cybin
How Cybin aims to maximize the potential of two classical psychedelics 
Biogen in the Drug Discovery & Development Pharma 50
Biogen halts observational post-marketing study of aducanumab

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50